[en] BACKGROUND: In-silico virtual patients and trials offer significant advantages in cost, time and safety for designing effective tight glycemic control (TGC) protocols. However, no such method has fully validated the independence of virtual patients (or resulting clinical trial predictions) from the data used to create them. This study uses matched cohorts from a TGC clinical trial to validate virtual patients and in-silico virtual trial models and methods. METHODS: Data from a 211 patient subset of the Glucontrol trial in Liege, Belgium. Glucontrol-A (N = 142) targeted 4.4-6.1 mmol/L and Glucontrol-B (N = 69) targeted 7.8-10.0 mmol/L. Cohorts were matched by APACHE II score, initial BG, age, weight, BMI and sex (p > 0.25). Virtual patients are created by fitting a clinically validated model to clinical data, yielding time varying insulin sensitivity profiles (SI(t)) that drives in-silico patients.Model fit and intra-patient (forward) prediction errors are used to validate individual in-silico virtual patients. Self-validation (tests A protocol on Group-A virtual patients; and B protocol on B virtual patients) and cross-validation (tests A protocol on Group-B virtual patients; and B protocol on A virtual patients) are used in comparison to clinical data to assess ability to predict clinical trial results. RESULTS: Model fit errors were small (<0.25%) for all patients, indicating model fitness. Median forward prediction errors were: 4.3, 2.8 and 3.5% for Group-A, Group-B and Overall (A+B), indicating individual virtual patients were accurate representations of real patients. SI and its variability were similar between cohorts indicating they were metabolically similar.Self and cross validation results were within 1-10% of the clinical data for both Group-A and Group-B. Self-validation indicated clinically insignificant errors due to model and/or clinical compliance. Cross-validation clearly showed that virtual patients enabled by identified patient-specific SI(t) profiles can accurately predict the performance of independent and different TGC protocols. CONCLUSIONS: This study fully validates these virtual patients and in silico virtual trial methods, and clearly shows they can accurately simulate, in advance, the clinical results of a TGC protocol, enabling rapid in silico protocol design and optimization. These outcomes provide the first rigorous validation of a virtual in-silico patient and virtual trials methodology.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Chase, J Geoffrey
Suhaimi, Fatanah
Penning, Sophie ; Université de Liège - ULiège > Département d'astrophys., géophysique et océanographie (AGO) > Thermodynamique des phénomènes irréversibles
Moorhead, Katherine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path. - Thermodynamique des phénomènes irréversibles
Desaive, Thomas ; Université de Liège - ULiège > Département d'astrophys., géophysique et océanographie (AGO) > Thermodynamique des phénomènes irréversibles - Département d'astrophys., géophysique et océanographie (AGO)
Language :
English
Title :
Validation of a model-based virtual trials method for tight glycemic control in intensive care.
Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000, 355:773-778. 10.1016/S0140-6736(99)08415-9, 10711923.
Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003, 78:1471-1478. 10.4065/78.12.1471, 14661676.
McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001, 17:107-124. 10.1016/S0749-0704(05)70154-8, 11219223.
Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab 2001, 15:533-551. 10.1053/beem.2001.0168, 11800522.
Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008, 36:3008-3013. 10.1097/CCM.0b013e31818b38d2, 18824908.
Ali NA, O'Brien JM, Dungan K, Phillips G, Marsh CB, Lemeshow S, Connors AF, Preiser JC. Glucose variability and mortality in patients with sepsis. Crit Care Med 2008, 36:2316-2321. 10.1097/CCM.0b013e3181810378, 18596625.
Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006, 105:244-252. 10.1097/00000542-200608000-00006, 16871057.
Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive Insulin Therapy in the Medical ICU. N Engl J Med 2006, 354:449-461. 10.1056/NEJMoa052521, 16452557.
Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367. 10.1056/NEJMoa011300, 11794168.
Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004, 79:992-1000. 10.4065/79.8.992, 15301325.
Chase JG, Shaw G, Le Compte A, Lonergan T, Willacy M, Wong X-W, Lin J, Lotz T, Lee D, Hann C. Implementation and evaluation of the SPRINT protocol for tight glycaemic control in critically ill patients: a clinical practice change. Critical Care 2008, 12:R49. 10.1186/cc6868, 18412978.
Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finfer S, Talmor D. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. Cmaj 2009, 2665940, 19318387.
Krinsley JS, Jones RL. Cost analysis of intensive glycemic control in critically ill adult patients. Chest 2006, 129:644-650. 10.1378/chest.129.3.644, 16537863.
Van den Berghe G, Wouters PJ, Kesteloot K, Hilleman DE. Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med 2006, 34:612-616.
Chase JG, Shaw G, Le Compte A, Lonergan T, Willacy M, Wong XW, Lin J, Lotz T, Lee D, Hann C. Implementation and evaluation of the SPRINT protocol for tight glycaemic control in critically ill patients: a clinical practice change. Crit Care 2008, 12:R49. 10.1186/cc6868, 2447603, 18412978.
Chase JG, Shaw GM, Lotz T, LeCompte A, Wong J, Lin J, Lonergan T, Willacy M, Hann CE. Model-based insulin and nutrition administration for tight glycaemic control in critical care. Curr Drug Deliv 2007, 4:283-296. 10.2174/156720107782151223, 17979649.
Le Compte A, Chase J, Lynn A, Hann C, Shaw G, Wong X, Lin J. Blood Glucose Controller for Neonatal Intensive Care: Virtual trials development and 1st clinical trials. Journal of Diabetes Science and Technology 2009, 3:1066-1081. 2769904, 20144420.
Lin J, Lee DS, Chase JG, Hann CE, Lotz T, Wong XW. Stochastic Modelling of Insulin Sensitivity Variability in Critical Care. Biomedical Signal Processing & Control 2006, 1:229-242.
Wong XW, Chase JG, Shaw GM, Hann CE, Lotz T, Lin J, Singh-Levett I, Hollingsworth LJ, Wong OS, Andreassen S. Model predictive glycaemic regulation in critical illness using insulin and nutrition input: a pilot study. Med Eng Phys 2006, 28:665-681. 10.1016/j.medengphy.2005.10.015, 16343972.
Lonergan T, Compte AL, Willacy M, Chase JG, Shaw GM, Hann CE, Lotz T, Lin J, Wong XW. A pilot study of the SPRINT protocol for tight glycemic control in critically Ill patients. Diabetes Technol Ther 2006, 8:449-462. 10.1089/dia.2006.8.449, 16939370.
Lonergan T, LeCompte A, Willacy M, Chase JG, Shaw GM, Wong XW, Lotz T, Lin J, Hann CE. A Simple Insulin-Nutrition Protocol for Tight Glycemic Control in Critical Illness: Development and Protocol Comparison. Diabetes Technol Ther 2006, 8:191-206. 10.1089/dia.2006.8.191, 16734549.
Lehmann ED, Deutsch T. AIDA2: A Mk. II automated insulin dosage advisor. J Biomed Eng 1993, 15:201-211. 10.1016/0141-5425(93)90116-G, 8320979.
Kovatchev BP, Breton M, Man CD, Cobelli C. In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes. Journal of diabetes science and technology (Online) 2009, 3:44-55.
Wilinska ME, Chassin L, Hovorka R. In Silico Testing--Impact on the Progress of the Closed Loop Insulin Infusion for Critically Ill Patients Project. Journal of Diabetes Science and Technology 2008, 2:417-423. 2769748, 19885206.
Suhaimi F, Le Compte A, Preiser JC, Shaw GM, Massion P, Radermecker R, Pretty C, Lin J, Desaive T, Chase JG. What Makes Tight Glycemic Control (TGC) Tight? The impact of variability and nutrition in 2 clinical studies. Journal of Diabetes Science and Technology 2010, 4:284-298.
Preiser J, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groeneveld J, Iapichino G, Leverve X, Nitenberg G, Singer P. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Medicine 2009, 35:1738-1748. 10.1007/s00134-009-1585-2, 19636533.
Hann CE, Chase JG, Lin J, Lotz T, Doran CV, Shaw GM. Integral-based parameter identification for long-term dynamic verification of a glucose-insulin system model. Comput Methods Programs Biomed 2005, 77:259-270. 10.1016/j.cmpb.2004.10.006, 15721654.
Wong XW, Singh-Levett I, Hollingsworth LJ, Shaw GM, Hann CE, Lotz T, Lin J, Wong OS, Chase JG. A novel, model-based insulin and nutrition delivery controller for glycemic regulation in critically ill patients. Diabetes Technol Ther 2006, 8:174-190. 10.1089/dia.2006.8.174, 16734548.
Chase JG, Shaw GM, Lin J, Doran CV, Hann C, Lotz T, Wake GC, Broughton B. Targeted glycemic reduction in critical care using closed-loop control. Diabetes Technol Ther 2005, 7:274-282. 10.1089/dia.2005.7.274, 15857229.
Chase JG, Shaw GM, Lin J, Doran CV, Hann C, Robertson MB, Browne PM, Lotz T, Wake GC, Broughton B. Adaptive bolus-based targeted glucose regulation of hyperglycaemia in critical care. Med Eng Phys 2005, 27:1-11. 10.1016/j.medengphy.2004.08.006, 15603999.
Blakemore A, Wang S, Le Compte A, Shaw G, Wong X, Lin J, Lotz T, Hann C, Chase J. Model-Based Insulin Sensitivity as a Sepsis Diagnostic in Critical Care. Journal of Diabetes Science and Technology 2008, 2:468-477. 2769723, 19885212.
Hann C, Chase J, Ypma M, Elfring J, Nor N, Lawrence P, Shaw G. The Impact of Parameter Identification Methods on Drug Therapy Control in an Intensive Care Unit. The Open Medical Informatics Journal 2008, 2:92-104. 10.2174/1874431100802010092, 2669646, 19415138.
Lotz TF, Chase JG, McAuley KA, Lee DS, Lin J, Hann CE, Mann JI. Transient and steady-state euglycemic clamp validation of a model for glycemic control and insulin sensitivity testing. Diabetes Technol Ther 2006, 8:338-346. 10.1089/dia.2006.8.338, 16800755.
Lotz TF, Chase JG, McAuley KA, Shaw GM, Wong XW, Lin J, Lecompte A, Hann CE, Mann JI. Monte Carlo analysis of a new model-based method for insulin sensitivity testing. Comput Methods Programs Biomed 2008, 89:215-225. 10.1016/j.cmpb.2007.03.007, 18242418.
Le Compte A, Lee DS, Chase JG, Lin J, Lynn A, Shaw GM. Blood Glucose Prediction Using Stochastic Modeling in Neonatal Intensive Care. IEEE Trans Biomed Eng 2010, 57:509-518. 10.1109/TBME.2009.2035517, 19884072.
Chase J, Shaw GM, Wong XW, Lotz T, Lin J, Hann CE. Model-based Glycaemic Control in Critical Care - A review of the state of the possible. Biomedical Signal Processing and Control 2006, 1:3-21.
Black PR, Brooks DC, Bessey PQ, Wolfe RR, Wilmore DW. Mechanisms of insulin resistance following injury. Ann Surg 1982, 196:420-435. 10.1097/00000658-198210000-00005, 1352701, 6751244.
Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1297. 10.1056/NEJMoa0810625, 19318384.
